Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults.
In an early-stage clinical trial led by the Dana-Farber Cancer Institute in Boston, a personalized vaccine prompted an anti-cancer immune response in all nine participants. These patients had been diagnosed with advanced disease and were given the vaccine after their tumors had been surgically removed. All remained cancer-free after a median follow-up period of just under three years. The trial results were published Feb. 5 in the journal Nature.
'Patients with Stage 3 or 4 kidney cancer are at high risk of recurrence,' Dr. Toni Choueiri, director of Dana-Farber's Lank Center for Genitourinary Cancer, said in a news release about the research. 'The tools we have to lower that risk are not perfect and we are relentlessly looking for more.'
Tumor removal is the current standard of late-stage ccRCC treatment. In 2021, the Food and Drug Administration approved Keytruda (pembrolizumab), an immunotherapy manufactured by Fortune 500 firm Merck, for post-surgical use in people with kidney cancer. While Keytruda may help lower a person's risk of cancer recurrence, it doesn't work for all patients.
Trial researchers, in a sense, manipulated each patient's cancer in an attempt to prevent it from coming back. That is, they fashioned personalized vaccines using the very fabric of the tumors that had been removed.
From the tumor tissue, researchers extracted neoantigens, which are bits of mutated proteins unique to cancer cells. Predictive algorithms helped the team gauge which neoantigens might elicit an immune response and should therefore be included in the vaccine. Dana-Farber has dubbed this biotechnology, which trains the immune system to destroy any remaining cancer cells, NeoVax.
Previous research has shown NeoVax to be potentially effective in treating melanoma. This form of skin cancer has more mutations than ccRCC, meaning it offers physician-scientists more neoantigens to draw from. That NeoVax appears promising in the treatment of kidney cancer is a win, researchers said.
'This approach is truly distinct from vaccine attempts in kidney cancer,' study coauthor Dr. David Braun, formerly of Dana-Farber and now a medical oncologist at Yale Cancer Center, said in the news release. 'We pick targets that are unique to the cancer and different from any normal part of the body, so the immune system can be effectively 'steered' toward the cancer in a very specific way.
'We learned which specific targets in the cancer are most susceptible to immune attack and demonstrated that this approach can generate long-lasting immune responses, directing the immune system to recognize cancer. We believe this work can form a foundation for the development of neoantigen vaccines in kidney cancer.'
Braun and Choueiri administered personalized vaccines to the nine trial patients, five of whom also received Yervoy (ipilimumab), an immunotherapy made by Fortune 500 company Bristol-Myers Squibb. Within three weeks, the vaccine triggered a promising immune response.
'We observed a rapid, substantial, and durable expansion of new T-cell clones related to the vaccine,' Dr. Patrick Ott, director of Dana-Farber's Center for Cancer Vaccines, said in the news release. T cells are a type of white blood cell critical to the immune system. Ott added that while the results are encouraging, 'larger-scale studies will be required to fully understand the clinical efficacy of this approach.'
In the meantime, Choueiri is involved in a mid-stage Merck-led trial, in which nearly 300 patients with kidney cancer are being given Keytruda and either a placebo or a personalized immunization similar to NeoVax.
For more on cancer:
Just one alcoholic drink a day can increase your risk of cancer. But most Americans don't know the dangers, new survey says
A 5-minute test can estimate your odds of developing breast cancer—but not if you're biracial
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
Women get dismissed by doctors—and it's led to devastating consequences for cancer, says the OB/GYN Olivia Munn credits with saving her life
Virtual colonoscopy lets you skip the scope. Here's what to know about the colorectal cancer screening Mark Cuban says saves time and money
This story was originally featured on Fortune.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Ancient carbon emissions from rivers may accelerate climate change: study
MILWAUKEE - An incredibly complex area of science with no simple answers, climate change is one of the most significant and most hotly debated topics in science. A groundbreaking new study published in the journal "Nature" adds to the complexity by upending long-held beliefs about carbon emissions from our rivers and streams. The backstory Until this study, scientists typically thought most carbon dioxide – CO₂ – released from rivers originated from carbon that had been absorbed from the atmosphere since around 1955. That date is important because it marks the year when nuclear weapons testing sharply increased atmospheric radiocarbon, making it easier to distinguish newer carbon from older sources through radiocarbon dating. The study revealed that, in fact, nearly 60% of that CO₂ actually comes from ancient carbon. Some of that carbon could be thousands of years old. By the numbers Rivers and streams emit nearly 2 billion tons of CO₂ into the atmosphere annually. Only 41% of that CO₂ comes from after 1955, and the remaining 59% originates from ancient sources. The study analyzed nearly 1,200 river samples globally. Large rivers and those in arid, mountainous or carbonate-rich landscapes emit the most ancient carbon. FREE DOWNLOAD: Get breaking news alerts in the FOX LOCAL Mobile app for iOS or Android Why you should care Carbon emissions, both human-induced and natural, are the main cause of climate change. The presence of this ancient carbon suggests our landscapes store more human-emitted CO₂ than previously estimated. Climate change itself, along with erosion and land-use changes, could accelerate the release of this ancient carbon, which could then amplify the warming of our atmosphere. The study shifts how we understand what is known as the "carbon budget," or the balance of carbon sources that are critical to climate modeling. The Good News More carbon may be stored in land than we thought. Because only 41% of the carbon dioxide released from rivers and streams into the atmosphere comes from modern carbon, the study suggests that land-based ecosystems are holding onto more human-emitted carbon than previously believed. That means forests, soils and underground reservoirs may be buffering some of the impact of climate change better than climate models have indicated. While the massive amounts of older carbon are a concern, it is leaking out far more slowly, which could give scientists and policymakers more time to implement mitigation strategies. It's a reminder that the Earth's systems are very complex and potentially more resilient than some have thought. What's next Pinpointing the precise age of river- and stream-based CO₂ remains difficult due to seasonal and geographic variability in water flow. Future studies need to conduct high-resolution measurements to track carbon age across time and locations, and researchers need to further examine how climate-driven changes – like droughts, heavy rain and flooding – can affect carbon release patterns. SIGN UP TODAY: Get daily headlines, breaking news emails from FOX6 News There's also a pressing need to assess whether ancient carbon is being released at a faster pace in response to human activity and environmental change. The "Nature" study helps us respect our planet for its resilience but also reminds us of our need to treat our home with respect. The Source Information in this report is from the FOX6 Weather Experts and: Dean, J. F., et al. (2025). Nature, 642, 105–111.
Yahoo
16 hours ago
- Yahoo
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
Two healthcare Dow stocks stunned investors with their sharp falls in May. The worst-performing Dow stock last month plunged over 26% as things took an unexpected turn. 10 stocks we like better than UnitedHealth Group › The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow stocks in May -- both from the healthcare sector -- kept the index's rally in check, with one of them plunging over 25%. Shares of UnitedHealth Group (NYSE: UNH) crashed 26.6% in May after multiple negative developments sent shockwaves through the investing community. In mid-May, UnitedHealth suddenly replaced its CEO, Andrew Witty, with former CEO Stephen J. Hemsley with immediate effect and suspended its earnings outlook for the full year because of a surge in medical costs. In between, The Wall Street Journal reported a criminal investigation against UnitedHealth by the Department of Justice for a "possible medicare fraud." Days later, The Guardian released a scathing report alleging UnitedHealth put patients' health at risk by paying secret bonuses to nursing homes to cut hospital transfers. For now, UnitedHealth expects to "return to growth" in 2026 and has sued The Guardian for defamation. Regaining investor confidence, however, may not be easy. The stock is down 38% so far this year, as of this writing. Merck (NYSE: MRK) stock lost 9.8% in May and plunged to its 52-week low of $73.31 a share after President Donald Trump signed an executive order directing drugmakers in the U.S. to cut the prices of prescription drugs. This comes at a time when Merck already expects tariffs to add $200 million to its costs this year. Investors are also worried about Merck's future once its blockbuster oncology drug Keytruda loses patent exclusivity. In mid-May, analysts at Citi slashed Merck stock's price target to $84 per share from $115 per share citing the pharmaceutical company's growth challenges and a "lack of urgency" to develop a business that could soften the impact of a potential loss of up to 20% of sales for Keytruda once its patent expires. Merck, however, has a strong pipeline, remains committed to dividend growth, and yields 3.9%. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Citigroup is an advertising partner of Motley Fool Money. Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
New T-Rex ancestor discovered in drawers of Mongolian institute
Misidentified bones that languished in the drawers of a Mongolian institute for 50 years belong to a new species of tyrannosaur that rewrites the family history of the mighty T-Rex, scientists said Wednesday. This slender ancestor of the massive Tyrannosaurus Rex was around four metres (13 feet) long and weighed three quarters of a tonne, according to a new study in the journal Nature. "It would have been the size of a very large horse," study co-author Darla Zelenitsky of Canada's University of Calgary told AFP. The fossils were first dug up in southeastern Mongolia in the early 1970s but at the time were identified as belonging to a different tyrannosaur, Alectrosaurus. For half a century, the fossils sat in the drawers at the Institute of Paleontology of the Mongolian Academy of Sciences in the capital Ulaanbaatar. Then PhD student Jared Voris, who was on a trip to Mongolia, started looking through the drawers and noticed something was wrong, Zelenitsky said. It turned out the fossils were well-preserved, partial skeletons of two different individuals of a completely new species. "It is quite possible that discoveries like this are sitting in other museums that just have not been recognised," Zelenitsky added. - 'Messy' family history - They named the new species Khankhuuluu mongoliensis, which roughly means the dragon prince of Mongolia because it is smaller than the "king" T-Rex. Zelenitsky said the discovery "helped us clarify a lot about the family history of the tyrannosaur group because it was really messy previously". The T-Rex represented the end of the family line. It was the apex predator in North America until 66 million years ago, when an asteroid bigger than Mount Everest slammed into the Gulf of Mexico. Three quarters of life on Earth was wiped out, including all the dinosaurs that did not evolve into birds. Around 20 million years earlier, Khankhuuluu -- or another closely related family member -- is now believed to have migrated from Asia to North America using the land bridge that once connected Siberia and Alaska. This led to tyrannosaurs evolving across North America. Then one of these species is thought to have crossed back over to Asia, where two tyrannosaur subgroups emerged. One was much smaller, weighing under a tonne, and was nicknamed Pinocchio rex for its long snout. The other subgroup was huge and included behemoths like the Tarbosaurus, which was only a little smaller than the T-rex. One of the gigantic dinosaurs then left Asia again for North America, eventually giving rise to the T-Rex, which dominated for just two million years -- until the asteroid struck. dl/gil
